Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, non-peptidyl small-molecule agonist of human thrombopoietin receptor, c-mpl

Thrombocytopenia results from a decrease in platelets due to either increased platelet destruction and/or inadequate platelet production. This is a common problem in the management of patients with cancer and other conditions that affect hematopoietic cells including myelodysplastic syndrome, idiopathic thrombocytopenic purpura (ITP), chronic liver disease, and acquired immunodeficiency syndrome [1-7]. Thrombopoietin (TPO) increases platelet production through stimulation of proliferation and differentiation of megakaryocytic progenitor cells and induction of megakaryocyte maturation [8].

Source: Experimental Hematology - December 20, 2017 Category: Hematology Authors: Hiroshi Yoshida, Hajime Yamada, Wataru Nogami, Keiji Dohi, Tomomi Kurino-Yamada, Koji Sugiyama, Koji Takahashi, Yoshinari Gahara, Motoji Kitaura, Minoru Hasegawa, Itsuki Oshima, Kenji Kuwabara Source Type: research